ArticleMolecular pharmaceutics2012
Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers.
Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Molecular Dynamics Simulations and Their Novel Applications in Drug Delivery for Cancer Treatment: A Review.Annals of biomedical engineering · 2025Review
- Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.Pharmaceutics · 2025Review
- Drug delivery process simulation-Quantifying the conformation dynamics of paclitaxel and cremophor EL.PloS one · 2025Article
- A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer.Pharmaceutics · 2023Article
- Modification of Magnetite Nanoparticles with Triazine-Based Dendrons and Their Application as Drug-Transporting Systems.International journal of molecular sciences · 2021Article
- Two Decades of Triazine Dendrimers.Molecules (Basel, Switzerland) · 2021Review
- Optimization and computational studies evaluating molecular dynamics of EDA cored polymeric dendrimer.Scientific reports · 2020Article
- Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications.Pharmaceutics · 2020Review
- Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Dendrimer Prodrugs.Molecules (Basel, Switzerland) · 2016Review
- Prodrug Strategies for Paclitaxel.International journal of molecular sciences · 2016Review
- Nanoparticle Effects on Human Platelets in Vitro: A Comparison between PAMAM and Triazine Dendrimers.Molecules (Basel, Switzerland) · 2016Article
- Recent advances in targeted drug delivery approaches using dendritic polymers.Biomaterials science · 2015Article
- Molecular Modeling to Study Dendrimers for Biomedical Applications.Molecules (Basel, Switzerland) · 2014Review
- Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups.Molecular pharmaceutics · 2013Article
- Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide.Molecular diversity · 2013Article
- Dendrimers terminated with dichlorotriazine groups provide a route to compositional diversity.Organic letters · 2013Article
- Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Molecular pharmaceutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
The antitumor activities of triazine dendrimers bearing paclitaxel, a well-known mitotic inhibitor, are evaluated in SCID mice bearing human prostate cancer xenografts. To increase the activity of a first generation prodrug 1 that contained twelve paclitaxel molecules tethered via an ester linkage, the new construct described here, prodrug 2, tethers paclitaxel with linkers containing both an ester and disulfide. While PEGylation is necessary for solubility, and may improve biocompatibility and increase plasma half-life, it increases the heterogeneity of the sample with an average of eight to nine PEG chains (2 kDa each) incorporated. The heterogeneous population of PEGylated materials was used without fractionation based on models obtained from molecular dynamics simulations. Three models were examined; hexaPEGylated, nonaPEGylated, and dodecaPEGylated constructs. Intravenous delivery of prodrug 2 was performed by single, double or triple dosing regimes with doses spaced by one week. The doses varied from 50 mg of paclitaxel/kg to 200 mg of paclitaxel/kg. Tumor growth arrest and regression was observed over the 10-week treatment period without mortality for mice treated with the 50 mg of paclitaxel/kg treated three times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.